Compare DexCom, Inc. (DXCM) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs RLX Technology Inc — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while RLX Technology Inc trades at $1.73 (market cap $2.10B). The key difference: DexCom, Inc. is far larger — about 15.2× RLX Technology Inc's market cap, and RLX Technology Inc pays a 5.81% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and RLX Technology Inc for 35 Days on average.
| DXCM | RLX | |
|---|---|---|
Market Cap | $31.86B | $2.10B |
Volume | 3,607,070 | 1,079,706 |
Sector | Health | Consumer Staples |
52-Week High | $92.34 | $2.57 |
52-Week Low | $54.84 | $1.68 |
Typical Hold Time | 62 Days | 35 Days |
Enterprise Value | $31.32B | $832.26M |
Dividend Yield | — | 5.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
RLX Technology trades at $1.72, down 0.58% and near its 52-week low, with a bearish technical signal from moving averages. Fundamentally, the company shows solid profitability with 21.87% net income margin and attractive valuation metrics including P/E of 15.46 and P/B of 0.91. Recent quarterly earnings have consistently missed expectations, though revenue growth remains positive with 2026 projections showing $4.5B revenue and $985M net income.
The stock presents a value opportunity given discounted valuation, but faces headwinds from earnings misses and bearish technicals. International expansion through European acquisitions provides growth catalysts, though execution risks and margin compression require monitoring. Analyst sentiment remains cautious with 100% hold rating, suggesting limited near-term upside potential despite fundamental strengths.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
